Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02014909
Title A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Kolltan Pharmaceuticals, Inc.
Indications

melanoma

stomach cancer

lung non-small cell carcinoma

Her2-receptor positive breast cancer

head and neck cancer

colon cancer

Advanced Solid Tumor

Therapies

CDX-3379

CDX-3379 + Vemurafenib

CDX-3379 + Trastuzumab

CDX-3379 + Cetuximab

CDX-3379 + Erlotinib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST